Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.

Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.

Biosimilar drugs are intended to be as effective as the originator product but with a lower cost to healthcare systems. In our center we promoted a switch from originator infliximab (IFXor) to biosimilar infliximab (CT-P13). We analyzed efficacy, safety, immunogenicity and cost savings of switching....

Full description

Bibliographic Details
Main Authors: Ana Valido, Joana Silva-Dinis, Maria João Saavedra, Inês Iria, João Gonçalves, João Paulo Lopes, João Eurico Fonseca
Format: Article
Language:English
Published: Sociedade Portuguesa de Reumatologia 2019-10-01
Series:Acta Reumatológica Portuguesa
Subjects:
biosimilar
switch
ct-p13
infliximab
Online Access:http://www.actareumatologica.pt/files/article/1274_efficacy_immunogenicity_and_cost_analysis_of_a_systematic_switch_from_originator_infliximab_to_biosimilar_ct_p13_of_all_patients_with_inflammatory_arthritis_from_a_single_center__file.pdf

Internet

http://www.actareumatologica.pt/files/article/1274_efficacy_immunogenicity_and_cost_analysis_of_a_systematic_switch_from_originator_infliximab_to_biosimilar_ct_p13_of_all_patients_with_inflammatory_arthritis_from_a_single_center__file.pdf

Similar Items